Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer
The DOI matches its Crossref record.
Abstract
PURPOSE: To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m 2 intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m 2/d orally on days 1 to 14, methotrexate 40 mg/m 2 IV on days 1 and 8, fluorouracil 600 mg/m 2 IV on days 1 and 8, and prednisone 40 mg/m 2/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy. RESULTS: A total of 209 eligible patients were randomized with a median survival duration of 17.3 months for paclitaxel and 13.9 months for CMFP. Multivariate analysis showed that patients who received paclitaxel survived significantly longer than those who received CMFP (P = .025). Paclitaxel produced significantly less severe leukopenia, thrombocytopenia, mucositis, documented infections (all P < .001), nausea or vomiting (P = .003), and fever without documented infection (P = .007), and less hospitalization for febrile neutropenia than did CMFP (P = .001). Alopecia, peripheral neuropathy, and myalgia or arthralgia were more severe with paclitaxel (all P < .0001). Overall, quality of life was similar for both treatments (P ≥ .07). CONCLUSION: Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., Rubenstein, E. B., et al. (2004) · Cancer · doi:10.1002/cncr.20162 · Cited by 1,417
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
Mauri, D., Polyzos, N. P., Salanti, G., Pavlidis, N., & Ioannidis, J. P. A. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn414 · Cited by 523
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., Rolski, J., Melemed, A. S., Reyes-Vidal, J. M., Sekhon, J. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9362 · Cited by 425
The Cancer Patient and Quality of Life
Bottomley, A. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2-120 · Cited by 378
Crown, J., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 352
Jassem, J., Pieńkowski, T., Płuzańska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1707 · Cited by 308
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 305
Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint
Sudo, T., Nitta, M., Saya, H., & Ueno, N. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2013 · Cited by 262
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Health related quality of life in different states of breast cancer
Lidgren, M., Wilking, N., Jönsson, B., & Rehnberg, C. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9202-8 · Cited by 224
“New treatments have increased the survival of breast cancer patients, but some are associated with adverse effects and toxicity [3–5].”
BackgroundChemotherapy for breast cancer (Review)
Hassan (2010) · Oncology Reports · doi:10.3892/or_00000963 · Cited by 197
Taxane-containing regimens for metastatic breast cancer
Ghersi, D., Willson, M. L., Chan, M. M. K., Simes, J., Donoghue, E., & Wilcken, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003366.pub3 · Cited by 189
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-617 · Cited by 177
Denduluri, N., Low, J. A., Lee, J. J., Berman, A. W., Walshe, J. M., Vatas, U., Chow, C. K., Steinberg, S. M., Yang, S. X., & Swain, S. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0784 · Cited by 165
“Bone marrow suppression, an issue with taxanes and other schedules of ixabepilone, was not predominant in our patients.(20,26,27,29) Only one patient had neutropenia requiring growth factor support and delay in ixabepilone therapy.”
Background
Metadata
- Authors
- Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H. N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J., Stephenson, J., & Canetta, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-08
- Volume
- 17
- Issue
- 8
- Pages
- 2355-2355
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1924346446
- Cited by
- 209
- References
- 0
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.